Aclaris Therapeutics, Inc. (LON:0H8T)
3.300
-0.068 (-2.02%)
At close: Feb 12, 2026
Aclaris Therapeutics Revenue
Aclaris Therapeutics had revenue of $3.30M USD in the quarter ending September 30, 2025, a decrease of -24.09%. This brings the company's revenue in the last twelve months to $15.74M, down -41.87% year-over-year. In the year 2024, Aclaris Therapeutics had annual revenue of $18.72M, down -40.09%.
Revenue (ttm)
$15.74M
Revenue Growth
-41.87%
P/S Ratio
22.82
Revenue / Employee
$245.97K
Employees
64
Market Cap
267.24M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 18.72M | -12.53M | -40.09% |
| Dec 31, 2023 | 31.25M | 1.50M | 5.03% |
| Dec 31, 2022 | 29.75M | 22.99M | 340.05% |
| Dec 31, 2021 | 6.76M | 279.00K | 4.30% |
| Dec 31, 2020 | 6.48M | 2.26M | 53.35% |
| Dec 31, 2019 | 4.23M | -1.92M | -31.28% |
| Dec 31, 2018 | 6.15M | 4.47M | 265.48% |
| Dec 31, 2017 | 1.68M | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.64B |
| GSK plc | 32.67B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Integrated Diagnostics Holdings | 114.96M |
| Optima Health | 113.75M |
| Animalcare Group | 81.07M |
| Tristel | 46.46M |
Aclaris Therapeutics News
- 13 days ago - Aclaris Therapeutics (ACRS) Receives Buy Rating with $10 Target - GuruFocus
- 14 days ago - Looking Into Aclaris Therapeutics Inc's Recent Short Interest - Benzinga
- 16 days ago - Aclaris Hair Loss Drug Shows Faster Results Than Pfizer's Drug - Benzinga
- 16 days ago - Aclaris Therapeutics (ACRS) Reports Promising Preclinical Outcomes for Alopecia Treatment - GuruFocus
- 16 days ago - Aclaris Therapeutics' Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA) - GlobeNewsWire
- 4 weeks ago - Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052 - GlobeNewsWire
- 5 weeks ago - Aclaris Therapeutics, Inc. (ACRS) Discusses Positive Interim Results From ATI-052 Phase 1a Trial and Potential Therapeutic Advantages - Slideshow - Seeking Alpha
- 5 weeks ago - Aclaris Therapeutics, Inc. (ACRS) Discusses Positive Interim Results From ATI-052 Phase 1a Trial and Potential Therapeutic Advantages Transcript - Seeking Alpha